泽漆汤治疗肺腺癌潜在靶点预测及作用机制研究  

Study on prediction of potential targets and mechanism of Zeqi Decoction in the treatment of lung adenocarcinoma

作　　者：张旭芳 彭涛 周文静 闫润红 Zhang Xufang;Peng Tao;Zhou Wenjing;Yan Runhong(School of Basic Medical Sciences,Shanxi University of Chinese Medicine,Jinzhong 030619,China;Oncology Department,Shanxi Hospital of Integrated Traditional Chinese and Western Medicine,Taiyuan 030013,China)

机构地区：[1]山西中医药大学基础医学院,晋中030619 [2]山西省中西医结合医院肿瘤科,太原030013

出　　处：《国际中医中药杂志》2023年第7期861-867,共7页International Journal of Traditional Chinese Medicine

基　　金：山西省医学重点科研项目(2020XM26);山西省科技厅青年基金项目(20210302123314)。

摘　　要：目的利用生物信息学方法及体外实验探讨泽漆汤治疗肺腺癌的潜在分子靶标及作用机制。方法基于TCMSP及文献检索,收集泽漆汤活性成分,利用R软件筛选TCGA和GEO数据库中的肺腺癌差异表达基因,并通过加权基因共表达网络分析(WGCNA)得到共表达模块,与泽漆汤靶标匹配映射后获取潜在作用靶点,并对靶点进行GO功能和KEGG通路富集分析。对结果进行实验验证,取肺腺癌细胞株A549、H1299,按随机数字表法分为空白对照组和泽漆汤组。采用细胞增殖实验(CCK-8)检测细胞增殖抑制率,采用Western blot法检测A549、H1299细胞白细胞分化抗原36(CD36)的表达,采用ELISA法检测低密度脂蛋白受体(LDLR)、IL-6水平。结果获得泽漆汤抗肺腺癌活性成分157个,潜在靶点18个,主要包括CD36、IL6、LDLR等。泽漆汤治疗肺腺癌的主要靶点集中在脂质代谢相关途径。实验结果显示,泽漆汤可有效抑制A549、H1299细胞活力和CD36、LDLR、IL-6水平。结论泽漆汤可通过下调CD36、LDLR蛋白表达抑制炎症反应,减缓肺腺癌细胞增殖。Objective To explore the potential molecular targets and mechanism of Zeqi Decoction in the treatment of lung adenocarcinoma(LUAD)through bioinformatics and cell experiment.Methods The active components of Zeqi Decoction were collected based on TCMSP database and literature search.Then R software was used to screen differentially expressed genes in LUAD from TCGA and GEO databases.The co-expression module was obtained through weighted gene co-expression network analysis(WGCNA),and the potential targets were obtained after matching and mapping with targets of Zeqi Decoction.Enrichment analysis of GO function and KEGG pathway of targets was conducted.The results were experimentally verified.The lung adenocarcinoma cell lines A549 and H1299 were divided into blank control group and Zeqi Decoction group according to random number table.The inhibition rate of cell proliferation was detected by cell proliferation test(CCK-8);the expression of leukocyte differentiation antigen 36(CD36)in A549 and H1299 cells was detected by Western blot;the levels of low density lipoprotein receptor(LDLR)and IL-6 were detected by ELISA.Results Totally 157 anti-lung adenocarcinoma active components and 18 potential targets were obtained,mainly including CD36,IL6,LDLR,etc.The main target of Zeqi Decoction in the treatment of lung adenocarcinoma was lipid metabolism.The results showed that Zeqi Decoction could effectively inhibit the activity of A549 and H1299 cells and the levels of CD36,LDLR and IL-6.Conclusion Zeqi Decoction can inhibit the inflammatory response by down-regulating the protein expressions of CD36 and LDLR,thereby slowing the proliferation of cells.

关 键 词：肺腺癌 泽漆汤 生物信息学 细胞实验 

分 类 号：R285[医药卫生—中药学]